Digoxin for Patients With Non-alcoholic Steatohepatitis (NASH)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2020-06-01

Study Completion Date

2023-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess if digoxin is safe and efficacious in treating patients with non-alcoholic steatohepatitis (NASH) within the approved target range of 0.7 to 1 ng/ml.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis

NCT01766713

Non Alcoholic Steatohepatitis

COMPLETED PHASE2

Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)

NCT02443116

Nonalcoholic Steatohepatitis (NASH)

COMPLETED PHASE2

A Randomized, Double-blind, Placebo-controlled Study of ZSP1601 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)

NCT05692492

Nonalcoholic Steatohepatitis (NASH)

ACTIVE_NOT_RECRUITING PHASE2

Treatment of Nonalcoholic Steatohepatitis With Pioglitazone

NCT00013598

Fatty Liver Nonalcoholic Steatohepatitis

COMPLETED PHASE2

Study of ADI-PEG 20 Versus Placebo in Subjects With NASH

NCT05842512

Nonalcoholic Steatohepatitis (NASH)

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a phase II, open labeled, multi-center, prospective, randomized, placebo controlled clinical trial to evaluate the efficacy and safety of digoxin in the treatment of nonalcoholic steatohepatitis. The participants will take study drug digoxin, which is approved by FDA for the treatment of congestive heart failure (CHF), orally daily based on the body weight, titrated to the level of 0.7 to 1 ng/ml for total of 6 cycles (4 weeks/cycle). A liver biopsy will be performed at the beginning of the study and 24 weeks after randomization to evaluate the efficacy of digoxin in the treatment of nonalcoholic steatohepatitis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nonalcoholic Steatohepatitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Digoxin tablet

Patients will be given digoxin orally daily for 24 weeks. The initial dose will be selected with the goal of achieving a serum digoxin concentration of 0.7-1 ng/ml, a dose range recommended for heart failure patients. A dose of 0.0625, 0.125 or 0.25 mg daily will be selected based on a normogram.

Group Type EXPERIMENTAL

Digoxin tablet

Intervention Type DRUG

The NASH patients in experimental group will take digoxin tablets orally with the goal of achieving a serum digoxin concentration of 0.7-1 ng/ml for 24 weeks.

Placebo

Digoxin-like oral placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

The control group will receive the digoxin-like placebo treatment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Digoxin tablet

The NASH patients in experimental group will take digoxin tablets orally with the goal of achieving a serum digoxin concentration of 0.7-1 ng/ml for 24 weeks.

Intervention Type DRUG

Placebo

The control group will receive the digoxin-like placebo treatment.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Able to understand and willing to voluntarily sign an informed consent form (ICF) and Health Insurance Portability and Accountability Act (HIPAA) authorization.
2. Males or females between 18-70 years old with a clinically confirmed diagnosis of NASH within the last 12 months of Screening Visit.
3. BMI between 25 and 45 kg/m2.
4. Negative urine drugs-of-abuse screen.
5. Negative alcohol screen.
6. Negative urine pregnancy test and agree to use a medically acceptable method of contraception throughout the study and for 1 month after completing the study. Medically acceptable methods of contraception that may be used by the subject and/or partner include, but are not limited to: abstinence, oral contraception, NuvaRing® or transdermal systems, diaphragm with vaginal spermicide, intra uterine device, condom and partner using vaginal spermicide, at least 6 months after surgical sterilization, progestin implant or injection, or postmenopausal female (no menstrual period for \> 2 years) or vasectomy (\>6 months).
7. Normal EKG.
8. Deemed normal age-adjusted creatinine level.
9. NAS score greater than 5.
10. Steatosis greater than 8% on liver biopsy. Able and willing to comply with the protocol and available for all scheduled clinic visits and telephone calls.

Exclusion Criteria

1. Known cardiovascular disease
2. Subjects who have previously received digoxin or who have history of hypersensitivity, allergy, intolerance or contraindication to digoxin.
3. Requiring any of the following medications during the duration of the study:

* Potassium-depleting diuretics
* Calcium, particularly if administered rapidly by the intravenous route
* Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, erythromycin, clarithromycin (and possibly other macrolide antibiotics), tetracycline, propantheline, diphenoxylate, antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, metoclopramide, rifampin, quinine, penicillamine, thyroid hormone, sympathomimetics. Succinylcholine, calcium channel blockers, beta-blockers, carvedilol, and any drug that may cause a significant deterioration in renal function.
4. History of cirrhosis based on imaging or clinical criteria and/or hepatic decompensation including ascites, hepatic encephalopathy or variceal bleeding.
5. Platelet count \< 100,000/ul
6. Albumin below 3.5 g/dl
7. Serum ferritin \> 800 ng/mL
8. Anti-neutrophil antibody above 1: 160
9. International normalized ratio (INR) \> 1.2History of liver transplantation
10. History of hepatocellular carcinoma (HCC)
11. History of malignancy within the past 5 years or ongoing malignancy other than basal cell carcinoma, or resected noninvasive cutaneous squamous carcinoma at the time of Screening visit
12. Active, serious infections that requires parenteral antibiotic or antifungal therapy within 30 days prior to Screening visit.
13. Any ≥Grade 3 laboratory abnormality as defined by Toxicity Grading Scale, with the following exceptions unless clinical assessment foresees an immediate health risk to the subject:

* Subjects with pre-existing diabetes or with asymptomatic glucose ≥Grade 3 elevations;
* Subjects with asymptomatic triglyceride or cholesterol ≥Grade 3 elevations;
* Subjects with asymptomatic ALT and/or AST \> 4 time above normal
14. Females who are pregnant or breastfeeding.
15. Current or anticipated treatment with radiation therapy, cytotoxic chemotherapeutic agents and immunomodulating agents (such as systemic corticosteroids, interleukins, interferons).
16. Use of any experimental medications within the last 6 months of Screening Visit.
17. Any other clinically significant disorders or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study or unable to comply with the dosing and protocol requirements.
18. Familial dyslipidemia.
19. Weight loss of \>5% within 6 months prior to Screening, based on subject's reporting
20. Currently or participated in a weight loss program within the last 6 months.
21. Any history of bariatric surgery.
22. Diabetes mellitus Type I
23. Daily alcohol intake \>20 ml (2 units)/day for women and 30 ml (3 units)/day for men (on average), as per Alcohol Use Disorders Identification Test (AUDIT) questionnaire at Screening and plan to consume the same alcohol amount referenced above during the trial.
24. Hemoglobin A1c \>9.0%
25. Treatment initiation or dose change within 3 months of Screening with Vitamin E, or any of the following anti- diabetic medications: DPP-4 inhibitor, GLP-1 receptor agonists (such as Januvia \[sitagliptin\], Byetta \[incretin\], etc.), pioglitazone, or SGLT2 inhibitors ("gliflozin" drugs), Metformin, fibrates, statins, insulin, Vitamin D, or sulfonylurea.
26. Use of any immunosuppressive medication, anti-inflammatory monoclonal antibody treatment, or chronic systemic corticosteroids \>10 mg prednisone-equivalent concurrently or within 1 year prior to Screening.
27. Uncontrolled or clinically unstable thyroid disease, in the judgment of the Principal Investigator.
28. History or presence of hepatitis B or C or human immunodeficiency virus (HIV).
29. Uncontrolled arterial hypertension
30. Any severe, acute, or chronic medical or psychiatric condition that may increase the risk associated with study participation or study drug administration, may interfere with the informed consent process and/or with compliance with the requirements of the study, or may interfere with the interpretation of study results and, in the investigator's opinion, would make the subject inappropriate for entry into this study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No